financetom
Business
financetom
/
Business
/
Pantera-Backed Solana Company Brings Forward PIPE Unlock as Stock Price Plunges 60%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pantera-Backed Solana Company Brings Forward PIPE Unlock as Stock Price Plunges 60%
Oct 20, 2025 1:14 PM

Solana Company ( HSDT ) , the digital asset treasury firm formerly known as Helius Medical Technologies and backed by Pantera Capital, has moved ahead with unlocking shares for early investors in its $500 million PIPE round as the company’s stock trades below the initial purchase price.

The shares, sold in a private placement in September at $6.881 each, has become eligible for sale earlier than scheduled, the firm said in a Monday press release. HSDT shares have tumbled to around $6.50 following a steep three-session decline that wiped nearly 60% from its market value, including a 17% drop on Monday.

"'Ripping off the band-aid' is the approach we are confidently taking, while many other DATs are choosing to stall," the company posted on X on Monday.

"The pressure on our stock price that comes with the effectiveness of the resale registration statement will likely shake out weak hands, but we believe this will also establish a remaining foundation of committed long-term shareholders," Joseph Chee, executive chairman of the firm, said in a statement.

Private placement in a public equity deals, or PIPE in short, allow institutional investors to buy shares of public companies at pre-set prices, often at a discount. It has become a favored method among recently launched digital asset treasury firms for raising capital quickly to accumulate cryptocurrencies.

However, several firms saw their stock prices collapse when sale registration for PIPE investors went live, raising doubts about the structure's sustainability in crypto markets.

HSDT's stock surged above $25 following the PIPE deal before plunging over 70% as the digital asset treasury hype across the market fizzled out.

Read more: The Rise and (Mostly) Fall of the PIPE Model in Bitcoin Treasury Strategies

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
From Mouse To Marvel: Disney Stock Rockets 50% As CEO Bob Iger Attempts Turnaround Plan
From Mouse To Marvel: Disney Stock Rockets 50% As CEO Bob Iger Attempts Turnaround Plan
Apr 4, 2024
The Walt Disney Co ( DIS ) stock has been on a tear the past six months. The stock has returned over 50% to investors, as CEO Bob Iger‘s turnaround plans take the desired effect. So far in 2024, it’s up over 32.50%. Disney ( DIS ) stock momentum is due to several catalysts, including: The company’s strong financial performance...
Drilling Deep: Analyst Outlines Chesapeake Merger Synergies, Delays Due To Regulatory Risks
Drilling Deep: Analyst Outlines Chesapeake Merger Synergies, Delays Due To Regulatory Risks
Apr 4, 2024
Keybanc Capital Market analyst Tim Rezvan initiated coverage on Chesapeake Energy Corporation ( CHK )  at Sector Weight rating. The rating reflects the near/medium-term outlook for natural gas. The analyst says management is acting prudently by curtailing production amid weak prices.  The analyst writes that significant synergies can be extracted from the Southwestern merger and believes management is proving to be a first-mover with its push...
Hedge funds rally in Q1, powered by gains in equities
Hedge funds rally in Q1, powered by gains in equities
Apr 4, 2024
NEW YORK (Reuters) -Hedge funds capped the first quarter with gains across different strategies, as a rally in stocks, some commodities and the dollar helped the industry weather a less shiny period for bonds, investors said. Fundamental equities long/short hedge funds were up 6.28% in the first quarter, while systematic long/short funds posted gains of 11%, according to a Goldman...
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial
Apr 4, 2024
02:12 PM EDT, 04/04/2024 (MT Newswires) -- ADC Therapeutics ( ADCT ) rose past 10% in recent Thursday trading after the company said it completed dose escalation in its phase 1b trial of Zynlonta plus glofitamab or mosunetuzumab in patients with relapsed/refractory B-cell non-hodgkin lymphoma. There were no dose-limiting toxicities, no or low-grade cytokine release syndrome, and no immune effector...
Copyright 2023-2026 - www.financetom.com All Rights Reserved